<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267771</url>
  </required_header>
  <id_info>
    <org_study_id>gehad elsherief</org_study_id>
    <nct_id>NCT03267771</nct_id>
  </id_info>
  <brief_title>Progesterone and Doppler in Recurrent Abortion</brief_title>
  <official_title>Role of Serum Progesterone and Doppler Ultrasound in Prediction of Pregnancy Outcome in Women With Recurrent Unexplained Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent pregnancy loss is classically defined as the occurrence of three or more
      consecutive pregnancy loss. The American Society of Reproductive Medicine has recently
      redefined recurrent pregnancy loss as two or more pregnancy losses. A pregnancy loss is
      defined as a clinically-recognized pregnancy means that the pregnancy has been visualized on
      an ultrasound or that pregnancy tissue was identified after a pregnancy loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spontaneous pregnancy loss is a surprisingly common occurrence. Whereas approximately 15% of
      all clinically recognized pregnancies result in spontaneous loss, there are many more
      pregnancies that fail prior to being clinically recognized. Only 30% of all conceptions
      result in a live birth.

      Although no reliable published data have estimated the probability of finding an etiology for
      recurrent pregnancy loss in a population with 2 versus 3 or more miscarriages, the best
      available data suggest that the risk of miscarriage in subsequent pregnancies is 30% after 2
      losses, compared with 33% after 3 losses among patients without a history of a live birth.
      This strongly suggests a role for evaluation after just 2 losses in patients with no prior
      live births. An earlier evaluation may be further indicated if fetal cardiac activity was
      identified prior to a loss .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of Live births after 28 weeks of gestation</measure>
    <time_frame>28 weeks gestation</time_frame>
    <description>Live births that survive and continue beyond 28 weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who Tolerable with the treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>efficacy of treatment on patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Abortion in First Trimester</condition>
  <arm_group>
    <arm_group_label>progesterone suppositories vaginal group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vaginal micronized progesterone suppositories (prontogest®) 400 mg, one vaginal suppository twice daily through 18 weeks of gestation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dydrogesterone oral tablets group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg tablets (Duphaston ®), 2 tablets orally twice daily through 18 weeks of gestation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone Suppositories Vaginal</intervention_name>
    <description>progesterone vaginal suppository</description>
    <arm_group_label>progesterone suppositories vaginal group</arm_group_label>
    <other_name>Prontogest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone Oral Tablet</intervention_name>
    <description>oral progesterone drug</description>
    <arm_group_label>Dydrogesterone oral tablets group</arm_group_label>
    <other_name>Duphaston</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>doppler ultrasound</intervention_name>
    <description>pulsed doppler ultrasound</description>
    <arm_group_label>progesterone suppositories vaginal group</arm_group_label>
    <arm_group_label>Dydrogesterone oral tablets group</arm_group_label>
    <other_name>Gomez et al</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pregnant 7-12 weeks documented by pregnancy test &amp;/or ultrasaound.

          2. History of at least 2 prior spontaneous abortion before 12 weeks of gestation.

          3. Age: 18-35 years

          4. Willing and able to give informed consent.

          5. Rh +ve patient

          6. BMI: 18-32

          7. Viable pregnancy through the detection of fetal pulsations by ultrasound

          8. Singleton pregnancy

          9. Apparently stable pregnancy (no history of vaginal bleeding in this current pregnancy
             or signs of sac separation in ultrasound)

        Exclusion Criteria:

          1. Patients diagnosed to have Anti-phospholipid syndrome or another recognised
             thrombophilic or autoimmune conditions.

          2. Pregnant &gt; 12 weeks.

          3. Contraindication to progesterone use.

          4. Diabetic patients, have glucose intolerance.

          5. Multiple pregnancies.

          6. Thyroid disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Ibrahim</last_name>
    <phone>01000024321</phone>
    <email>ahmedibrahimhas@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hesham Abu taleb</last_name>
    <phone>01003332139</phone>
    <email>Hishamaboutaleb1@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gehad Elsherief</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>gehad elsherief</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. Hum Reprod Update. 2002 Jul-Aug;8(4):333-43. Review.</citation>
    <PMID>12206468</PMID>
  </reference>
  <reference>
    <citation>Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management. BMJ. 2004 Jul 17;329(7458):152-5. Review.</citation>
    <PMID>15258071</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>GKElsherief</investigator_full_name>
    <investigator_title>prinicipal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

